Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD55.

[1]  Seyed Moein Moghimi,et al.  Immunoglobulin deposition on biomolecule corona determines complement opsonisation efficiency of preclinical and clinical nanoparticles , 2018, Nature Nanotechnology.

[2]  Yechezkel Barenholz,et al.  Roadmap and strategy for overcoming infusion reactions to nanomedicines , 2018, Nature Nanotechnology.

[3]  A. Alawieh,et al.  Targeted complement inhibition salvages stressed neurons and inhibits neuroinflammation after stroke in mice , 2018, Science Translational Medicine.

[4]  G. Arrigoni,et al.  C1q-Mediated Complement Activation and C3 Opsonization Trigger Recognition of Stealth Poly(2-methyl-2-oxazoline)-Coated Silica Nanoparticles by Human Phagocytes. , 2018, ACS nano.

[5]  D. Simberg,et al.  Translational gaps in animal models of human infusion reactions to nanomedicines. , 2018, Nanomedicine.

[6]  S. Moghimi.  Nanomedicine safety in preclinical and clinical development: focus on idiosyncratic injection/infusion reactions. , 2017, Drug discovery today.

[7]  E. Groman,et al.  Variability of Complement Response toward Preclinical and Clinical Nanocarriers in the General Population. , 2017, Bioconjugate chemistry.

[8]  S. Barnum.  Therapeutic Inhibition of Complement: Well Worth the Risk. , 2017, Trends in pharmacological sciences.

[9]  Seyed Moein Moghimi,et al.  Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo. , 2017, Nature nanotechnology.

[10]  John D Lambris,et al.  Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation. , 2017, Blood.

[11]  Yan Wang,et al.  Stealth Immune Properties of Graphene Oxide Enabled by Surface-Bound Complement Factor H. , 2016, ACS nano.

[12]  Guangwei Yang,et al.  Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome , 2016, Haematologica.

[13]  A. Gabizon,et al.  New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy. , 2016, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[14]  S. Alzghari,et al.  Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[15]  John D Lambris,et al.  Regulators of complement activity mediate inhibitory mechanisms through a common C3b‐binding mode , 2016, The EMBO journal.

[16]  A. Risitano,et al.  Safety and Pharmacokinetics of the Complement Inhibitor TT30 in a Phase I Trial for Untreated PNH Patients , 2015 .

[17]  B. Paul Morgan,et al.  Complement, a target for therapy in inflammatory and degenerative diseases , 2015, Nature Reviews Drug Discovery.

[18]  V. M. Holers,et al.  Modulatory Role of Surface Coating of Superparamagnetic Iron Oxide Nanoworms in Complement Opsonization and Leukocyte Uptake. , 2015, ACS nano.

[19]  T. Triche,et al.  Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression , 2015, Clinical Cancer Research.

[20]  Seyed Moein Moghimi,et al.  Mechanisms of complement activation by dextran-coated superparamagnetic iron oxide (SPIO) nanoworms in mouse versus human serum , 2014, Particle and Fibre Toxicology.

[21]  S. Russek,et al.  High-relaxivity superparamagnetic iron oxide nanoworms with decreased immune recognition and long-circulating properties. , 2014, ACS nano.

[22]  S M Moghimi,et al.  Cancer nanomedicine and the complement system activation paradigm: anaphylaxis and tumour growth. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[23]  John D Lambris,et al.  Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles. , 2014, Biomaterials.

[24]  John D Lambris,et al.  Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. , 2014, Blood.

[25]  S. Katti,et al.  The human complement receptor type 2 (CR2)/CR1 fusion protein TT32, a targeted inhibitor of the classical and alternative pathway C3 convertases, prevents arthritis in active immunization and passive transfer models and acts by CR2-dependent targeting of CR1 regulatory activity , 2012 .

[26]  Davoud Ahmadvand,et al.  Material properties in complement activation. , 2011, Advanced drug delivery reviews.

[27]  Kutty Selva Nandakumar,et al.  Inhibiting the C5-C5a receptor axis. , 2011, Molecular immunology.

[28]  D. Simberg,et al.  Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems , 2011, Expert opinion on drug delivery.

[29]  Jin Wu,et al.  Structures of C3b in Complex with Factors B and D Give Insight into Complement Convertase Formation , 2010, Science.

[30]  John D Lambris,et al.  Complement: a key system for immune surveillance and homeostasis , 2010, Nature Immunology.

[31]  Parag Aggarwal,et al.  Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. , 2008, Molecular pharmaceutics.

[32]  B. Nilsson,et al.  The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb). , 2008, Molecular immunology.

[33]  V. M. Holers,et al.  A Complement C3 Inhibitor Specifically Targeted to Sites of Complement Activation Effectively Ameliorates Collagen-Induced Arthritis in DBA/1J Mice1 , 2007, The Journal of Immunology.

[34]  R. Weissleder,et al.  Utility of a new bolus-injectable nanoparticle for clinical cancer staging. , 2007, Neoplasia.

[35]  Janos Szebeni,et al.  Methylation of the phosphate oxygen moiety of phospholipid‐methoxy(polyethylene glycol) conjugate prevents PEGylated liposome‐mediated complement activation and anaphylatoxin production , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  M. Teixeira,et al.  APT070 (Mirococept), a membrane‐localised complement inhibitor, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury , 2005, British journal of pharmacology.

[37]  G. Smith,et al.  Biological activity, membrane‐targeting modification, and crystallization of soluble human decay accelerating factor expressed in E. coli , 2004, Protein science : a publication of the Protein Society.

[38]  P Lukacik,et al.  Complement regulation at the molecular level: the structure of decay-accelerating factor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[39]  F M Muggia,et al.  Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  G. Smith,et al.  Membrane-targeted complement inhibitors. , 2001, Molecular immunology.

[41]  A. Gabizon.  Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy , 2001, Cancer investigation.

[42]  C. Mold,et al.  Structure/function studies of human decay‐accelerating factor , 2000, Immunology.

[43]  D. Fairlie,et al.  Effects of a new C5a receptor antagonist on C5a‐ and endotoxin‐ induced neutropenia in the rat , 1999, British journal of pharmacology.

[44]  K. Dimock,et al.  Short Consensus Repeat Domain 1 of Decay-Accelerating Factor Is Required for Enterovirus 70 Binding , 1998, Journal of Virology.

[45]  R. V. van Lier,et al.  The seven-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF) , 1996, The Journal of experimental medicine.

[46]  C. Mold,et al.  Localization of classical and alternative pathway regulatory activity within the decay-accelerating factor. , 1996, Journal of immunology.

[47]  R. Smith,et al.  Overexpression in Escherichia coli, folding, purification, and characterization of the first three short consensus repeat modules of human complement receptor type 1. , 1995, Protein expression and purification.

[48]  L. Matis,et al.  Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. , 1995, The Journal of clinical investigation.

[49]  D. Hourcade,et al.  Analysis of the functional domains of complement receptor type 1 (C3b/C4b receptor; CD35) by substitution mutagenesis. , 1994, The Journal of biological chemistry.

[50]  T. Fujita,et al.  Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor. , 1992, Journal of immunology.

[51]  J. Lambris,et al.  Structural and functional analysis of the complement component factor H with the use of different enzymes and monoclonal antibodies to factor H. , 1985, The Biochemical journal.

[52]  T. Lint,et al.  Activation of human complement by liposomes: a model for membrane activation of the alternative pathway. , 1979, Journal of immunology.

[53]  A. Lundberg,et al.  The human complement receptor type 2 (CR2)/CR1 fusion protein TT32, a novel targeted inhibitor of the classical and alternative pathway C3 convertases, prevents arthritis in active immunization and passive transfer mouse models , 2019, Molecular immunology.

[54]  Jennifer I. Hare,et al.  Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. , 2017, Advanced drug delivery reviews.

[55]  F. Wandosell,et al.  ImmunoPEGliposome-mediated reduction of blood and brain amyloid levels in a mouse model of Alzheimer's disease is restricted to aged animals. , 2017, Biomaterials.

[56]  V. Holers,et al.  CR2-mediated targeting of complement inhibitors: bench-to-bedside using a novel strategy for site-specific complement modulation. , 2013, Advances in experimental medicine and biology.

[57]  M. Bodó,et al.  The interaction of liposomes with the complement system: in vitro and in vivo assays. , 2003, Methods in enzymology.